BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that OptiNose, Inc. selected BioClinica Trident IWR, Optimizer clinical supplies forecasting, and Imaging Core Lab services for use in a series of clinical trials including several pivotal Phase III studies.
"OptiNose's goal was to employ the best available technology to help us develop the highest quality products in the most efficient manner," said Colette Kosik-Gonzalez, Senior Director, Clinical Development, OptiNose, Inc. "After a thorough competitive assessment of the leading solutions, we selected BioClinica for high-quality medical image management services and cutting-edge IVR technology to provide us with maximum efficiencies throughout our programs."
OptiNose's analysis found BioClinica Optimizer and Trident IWR products to be extremely user-friendly, with the added benefit of significantly reducing study build time. OptiNose also determined that the combination of Trident and Optimizer would ease trial management and help control costs by continually assessing clinical supply requirements throughout the trial.
"Award-winning technology and a talented services group are some of the reasons why innovative companies like OptiNose choose BioClinica's advanced imaging and IWR solutions," said Mark Weinstein, CEO of BioClinica. "BioClinica's approach to supporting clinical trials is based on the understanding that trial managers want better alternatives and fewer complications to support their clinical projects. With increasing frequency, clients realize the benefits of BioClinica's services suite and select multiple products to meet their needs. OptiNose is one such example of this trend, and we are pleased to help them manage their clinical trials with greater efficiency and accuracy."
BioClinica expands presence in Europe